Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

An innovative, non-thiazolidinedione pan-PPAR agonist therapeutic for alcoholic hepatitis: IND-enabling safety and toxicological evaluation

Award Number: R44AA029642
ORGANIZATION: NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 05/15/2022
PERIOD OF PERFORMANCE END DATE: 04/30/2027

Group Awards By:

View Award Description

An innovative, non-thiazolidinedione pan-PPAR agonist therapeutic for alcoholic hepatitis: IND-enabling safety and toxicological evaluation - PROJECT SUMMARY Alcoholic Hepatitis (AH) is a severe and acute form of alcohol-mediated liver disease, affecting ~34% of heavy alcohol drinkers and presents a healthcare burden of ~$2.2 billion/yearly. AH sufferers have a short life expectancy, with about ~70% of patients dying in the first six months after diagnosis. The high mortality rate of AH is largely due to lack of effective treatments for AH (e.g. corticosteroids) which do not increase patients’ survival and are linked to several secondary complications. Currently, the only effective cure for AH is early orthotopic liver transplantation which is not easily accessible, is extremely expensive, and requires life-long immunosuppression associated with long-term side effects. Pleiogenix proposes a unique therapeutic approach for AH, based on the novel, orally-active, non-thiazolidinedione pan-PPAR agonist (PLG888), optimized to selectively modulate the activities of all three PPAR isoforms. PLG888’s unique structural design enables full agonism of PPAR along with partial agonism towards PPAR and PPAR. This unique agonism profile, especially the partially PPAR agonism of PPAR overcomes the side effects (e.g. edema, weight gain, fractures) associated with full PPAR and PPARδ activation. Proof-of-concept data from Phase I of this project has revealed that PLG888 significantly increased the survival of ethanol-treated mice (NIAAA model), when compared to the clinical standard of care. Additionally, PLG888 significantly decreased liver transaminases (ALT and AST), inflammatory cytokines (TGFβ and TNFα), fibrosis markers, biliary hyperplasia, lobular inflammation and steatosis, without affecting total body weight or heart weight. The goal of this SBIR Phase II project is to establish the GLP safety and toxicology profile of PLG888 in rats and dogs. This project will also conduct polymorph and salt screening of PLG888 and characterize new forms, exhibiting enhanced thermodynamic stability and patentability. The successful completion of this proposed SBIR Phase II study will provide virtually all IND-enabling safety data, and also complete the IND-enabling CMC work pertaining to the chemical synthesis of PLG888. The successful execution of this proposed SBIR Phase II project will enable Pleiogenix to pursue a a) Phase IIb SBIR award to perform 3-month GLP-toxicity studies (rats, dogs) and to b) file an IND for AH indication to initiate clinical development of PLG888 for AH.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $1,025,643 )
2025	2025	PLEIOGENIX INC	2349 SUMMERWIND PL	CARLSBAD	CA	92008	SAN DIEGO	USA	Alcohol Research Programs	000	2	5/14/2025	COMPETING CONTINUATION	$1,025,643
														Subtotal = $1,025,643

Grand Total All Awards = $1,025,643

Top

All Categories

About

Search

Reports

Data Submission

Award Information

An innovative, non-thiazolidinedione pan-PPAR agonist therapeutic for alcoholic hepatitis: IND-enabling safety and toxicological evaluation

Award Number: R44AA029642

ORGANIZATION: NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 05/15/2022

PERIOD OF PERFORMANCE END DATE: 04/30/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer